Pericardial Effusion With Tamponade in Lung Cancer Patients During Treatment With Nivolumab: A Report of Two Cases

Background: Nivolumab is an immune checkpoint inhibitor (ICI) that has shown efficacy for treating non-small cell lung cancer and has become a standard therapy for previously treated non-small cell lung cancer. Moreover, immune-related adverse events of ICI therapy are well-known. Malignant pericard...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamasaki, Masahiro, Daido, Wakako, Saito, Naomi, Funaishi, Kunihiko, Okada, Takenori, Kawamoto, Kazuma, Matsumoto, Yu, Matsumoto, Naoko, Taniwaki, Masaya, Ohashi, Nobuyuki, Hattori, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349695/
https://www.ncbi.nlm.nih.gov/pubmed/30723699
http://dx.doi.org/10.3389/fonc.2019.00004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349695/
https://www.ncbi.nlm.nih.gov/pubmed/30723699
http://dx.doi.org/10.3389/fonc.2019.00004

Ejemplares similares